NCT01853748 2026-02-19
T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)
Dana-Farber Cancer Institute
Phase 2 Completed
Clinical Trials
14 trialsNCT01494662 2026-01-23
HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01975142 2025-11-24
Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment.
Institut Curie
Phase 2 Completed
NCT01565200 2025-03-31
ZEPHIR
Jules Bordet Institute
Phase 2 Completed
NCT03032107 2025-01-27
A Study Of Pembrolizumab In Combination With Trastuzumab-DM1
Dana-Farber Cancer Institute
Phase 1 Completed
NCT03530696 2024-08-13
T-DM1
University of Arizona
Phase 2 Completed
NCT02448420 2024-04-18
PATRICIA II
SOLTI Breast Cancer Research Group
Phase 2 Completed
NCT03364348 2022-10-19
4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer
Stanford University
Phase 1 Completed
NCT02562378 2022-02-23
THELMA
MedSIR
Phase 1 Completed
NCT01976169 2022-02-08
Phase 1b Study of PD-0332991 in Combination With T-DM1(Trastuzumab-DM1)
University of Texas Southwestern Medical Center
Phase 1 Completed
NCT01835236 2021-03-30
Trastuzumab & Pertuzumab Followed by T-DM1 in MBC
Swiss Cancer Institute
Phase 2 Completed
NCT02038010 2020-06-29
BYL719 + T-DM1 in HER2(+) Metastatic Breast Cancer Pts Who Progress on Prior Trastuzumab & Taxane Tx
Northwestern University
Phase 1 Completed
NCT02073916 2019-04-16
STELA
The Methodist Hospital Research Institute
Phase 1 Completed
NCT01816035 2017-05-23
Trastuzumab Emtansine in Treating Patients With HER2-Positive Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed by Surgery
University of Washington
Phase 1 Completed